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Studies suggest that in�ammation impairs reverse cholesterol transport (RCT). We investigated whether serum amyloid A
(SAA) contributes to this impairment using an established macrophage-to-feces RCT model. Wild-type (WT) mice and mice
de�cient in SAA1.1 and SAA2.1 (SAAKO) were injected intraperitoneally with 3H-cholesterol-labeled J774 macrophages 4 hr aer
administration of LPS or buffered saline. 3H-cholesterol in plasma 4 hr aer macrophage injection was signi�cantly reduced in
both WT and SAAKO mice injected with LPS, but this was not associated with a reduced capacity of serum from LPS-injected
mice to promote macrophage cholesterol efflux in vitro. Hepatic accumulation of 3H-cholesterol was unaltered in either WT or
SAAKO mice by LPS treatment. Radioactivity present in bile and feces of LPS-injected WT mice 24 hr aer macrophage injection
was reduced by 36% (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃 and 80% (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃, respectively. In contrast, in SAAKO mice, LPS did not signi�cantly reduce
macrophage-derived 3H-cholesterol in bile, and fecal excretionwas reduced by only 45% (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃. Injection of cholesterol-loaded
allogeneic J774 cells, but not syngeneic bone-marrow-derived macrophages, transiently induced SAA in C57BL/6 mice. Our study
con�rms reports that acute in�ammation impairs steps in the RCT pathway and establishes that SAA plays only a minor role in
this impairment.
1. Introduction
Epidemiological studies have identi�ed a strong inverse
relationship between the risk of cardiovascular disease and
plasma HDL levels [1]. One of the primary antiatherogenic
properties of HDL is thought to be its role in reverse choles-
terol transport (RCT), a process whereby excess cholesterol
is removed from peripheral tissues, including lipid-loaded
macrophages in the vessel wall, and transported to the liver
for excretion in the bile and feces [2]. Accelerated atheroscle-
rosis has been associated with in�ammatory diseases such
as rheumatoid arthritis [3], and in�ammatory biomarkers
are increasingly used as predictors of cardiovascular disease
progression [4, 5]. In�ammation gives rise to numerous
metabolic and structural changes in lipoproteins, particularly
HDL, which may impact the ability of HDL to mediate
RCT [6, 7]. In�ammatory HDL undergoes structural and
compositional changes, most notably an increase in its serum
amyloid A (SAA) content, to the extent that SAA can become
the major apolipoprotein of HDL [8]. SAA is a major hepatic
acute phase reactant and can account for as much as 2.5% of
the protein produced in the liver during severe in�ammation
[9]. During the acute phase, plasma SAA concentrations
rise rapidly with peak concentrations exceeding 1mg/mL.
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Approximately 95% of plasma SAA is associated with HDL
[8].
Two major acute phase SAA isoforms are expressed in
mice, SAA1.1 and SAA2.1, which are synthesized in the
liver upon in�ammatory cytokine stimulation [10]. Other
members of themurine SAA family include the constitutively
expressed SAA4 [11], which is a minor HDL protein, and
SAA3, which is primarily expressed extrahepatically, but does
not comprise a major protein of acute phase HDL [12].
Studies on the impact of SAA on HDL metabolism during
in�ammation are confounded by the fact that the in�am-
matory mediators that induce SAA also impact numerous
other metabolic systems, so that ascribing speci�c functions
to SAA becomes challenging. To delineate the speci�c impact
of acute phase SAAs on HDL metabolism and function, we
recently generated gene-targeted mice lacking both SAA1.1
and SAA2.1 (SAAKO mice) [13].
According to previous reports, macrophage RCT is
impaired in mice during an acute phase in�ammatory
response induced by LPS [14, 15] or zymosan [16]. In this
study, we determined the extent to which acute phase SAA1.1
and SAA2.1 contribute to this impairment by quantifying in
vivo macrophage RCT in wild-type (WT) and SAAKO mice
in the presence or absence of LPS-elicited endotoxemia. Our
results support the conclusion that in�ammation impairs
macrophage-to-feces RCT and that acute phase SAA has little
impact on this impairment. We also report that administra-
tion of cholesterol-loaded J774 macrophages, a commonly
used procedure in macrophage-to-feces RCT studies, inde-
pendently induces a transient acute phase response in mice.
2. Materials andMethods
2.1. Animals. C57BL/6 mice were obtained from Jackson
Laboratories. Mice lacking SAA1.1 and SAA2.1 were gen-
erated by targeted deletion of both mouse acute phase SAA
genes SAA1 and SAA2 (InGenious Targeting Laboratory Inc.,
Stony Brook, NY) using embryonic stem cells derived from
C57BL/6 ×129 SVEVmice as described previously [13]. Mice
weremaintained in a pathogen-free facility under equal light-
dark cycles with free access to water and food. All procedures
were carried out in accordancewith PHS policy and approved
by the Lexington Kentucky Veterans Affairs Medical Center
Institutional Animal Care and Use Committee (Assurance
number A3506-01).
2.2. Cell Culture
2.2.1. J774 Cells. J774 macrophages were kindly provided
by Dr. G.H. Rothblat (University of Pennsylvania) and
maintained in RPMI-1640 supplemented with 10% heat-
inactivated FBS and 50𝜇𝜇g/mL gentamicin. For in vivo RCT
experiments, cells were grown in suspension in HEPES-
buffered RPMI-1640 containing 10% heat-inactivated FBS
and 50 𝜇𝜇g/mL gentamicin. e cells were cholesterol loaded
for 24 hr in HEPES-buffered RPMI-1640 containing 1%
FBS, 25 𝜇𝜇g/mL acetylated LDL (acLDL), and 5 𝜇𝜇Ci/mL 3H-
cholesterol (35–50Ci/mmol,AmershamBiosciences).On the
day of injection, cells were washed, equilibrated for 2 hr
in HEPES-buffered RPMI-1640 containing 0.2% fatty acid
free BSA, centrifuged, and resuspended in minimal essential
media (MEM) prior to injection into mice (2.5 × 106 cells
in 0.5 mL). For some studies, J774 cells were prepared for
intraperitoneal injection intomice as described above, except
that 3H-cholesterol was omitted from the media during the
cholesterol loading step.
2.2.2. Bone-Marrow-Derived Macrophages (BMMs). BMMs
were harvested and cultured as described [17]. Brie�y, BMMs
were harvested from the tibias and femurs of C57BL/6 mice
5 days aer intraperitoneal injection of 1 mL 2% biogel beads
[18] by �ushing the bone cavities with PBS. Bone-marrow
was homogenized by drawing through an 18Gneedle andwas
maintained in sterile nontissue culture treated �asks using
RPMI-1640 supplemented with 1% P/S, 10% FBS, and 15%
L-cell-conditioned medium. e medium was changed on
days 3 and 5, and on day 6 BMM were treated for 24 hr
with RPMI 1640 containing 1% FBS, 1% P/S, and 25 𝜇𝜇g/mL
acLDL. On day 7 cells were equilibrated for 2 hr in RPMI-
1640 containing 0.2% fatty acid-free BSA, dislodged from
the tissue culture �ask with nonenzymatic cell dissociation
buffer (Sigma), centrifuged, and suspended in MEM prior to
intraperitoneal injection of 2.5 × 106 cells/0.5mL.
2.2.3. Rat Fu5AH Hepatoma Cells. Fu5AH cells, kindly pro-
vided by Dr. G.H. Rothblat (University of Pennsylvania),
were maintained in MEM supplemented with 5% FBS and
50 𝜇𝜇g/mL gentamicin.
2.3. Semiquantitative Real-Time PCR (RT-PCR). RT-PCR
was performed as described previously [13]. Brie�y, total
RNA was isolated from mouse liver using the TRIzol Reagent
(Molecular Research Center), and 10 𝜇𝜇g was treated with
TURBO DNA-Free DNAse (Ambion) according to the
manufacturer’s protocol. cDNA synthesis was performed
using 500 ng RNA and the Applied BiosystemsHighCapacity
cDNA kit. Ampli�cation was carried out using the iCycler
I�5 system (Bio-Rad). �uanti�cation was performed in
duplicate using the standard curve method and normalized
to GAPDH. e primers used are as follows: mSRBI,
NM_016741: forward 5′-CTTCATGACACCCGAATCCT-
3′, Reverse 5′-AATGCCTTCAAACACCCTTG-3′, 114bp;
mCyp7A1, NM_007824 forward 5′-AGCAACTAAACA-
ACCTGCCAGTACTA-3′, reverse 5′-GTCCGGATATTC-
AAGGATGCA-3′, 84bp; mABCA1, NM_013454: forward
5′-AGCCAGAAGGGAGTGTCAGA-3′, reverse 5′-CAT-
GCCATCTCGGTAAACCT-3′ 102bp; mABCG1, NM_
009593: forward 5′-AGGCCTACTACCTGGCAAAGA-3′,
reverse 5′-GCAGTAGGCCACAGGGAACA-3′, 68bp;
mABCG5, NM_031884: forward 5′-TGGATCCAACAC-
CTCTATGCTAAA-3′, reverse 5′-GGCAGGTTTTCTCGA-
TGAACTG-3′ 77bp; mABCG8, NM_026180: forward
5′-TGCCCACCTTCCACATGTC-3′, reverse 5′-ATGAAG-
CCGGCAGTAAGGTAGA-3′ 73bp; mABCB11,
NM_021022: forward 5′-AAGCTACATCTGCCTTAG-
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ACACAGAAA-3′, reverse 5′-CAATACAGGTCCGAC-
CCTCTCT-3′, 84bp.
2.4. In Vivo Macrophage RCT. RCT studies were carried
out in accordance with a well-established model [14, 19].
ree separate experiments were performed in ∼16-week-
old female SAAKO and WT mice (n = 4-5 per group
per experiment) that were housed in individual cages and
fed a normal rodent diet ad libitum. Anesthetized mice
received a subcutaneous injection of 0.8 𝜇𝜇g/g body weight
lipopolysaccharide (LPS; from E. coli 0111:B4, Sigma L 2630)
in ∼100𝜇𝜇L PBS or an injection of PBS alone. Aer 4 hr, mice
were administered intraperitoneally 2.5 × 106 radiolabeled
J774 macrophages (2.78–3.87 × 106 dpm/mouse) prepared as
described above. Blood was collected via retroorbital bleed
4 hr aer LPS administration and just prior to injection of
macrophages and then again 4 hr aer macrophage admin-
istration. Feces were collected throughout the course of the
study. Mice were euthanized 24 hr aer macrophage admin-
istration, and blood, bile, and liver were collected. To study
whether intraperitoneal injection of macrophages induces
an acute phase response in mice, BMM and J774 cells were
prepared as described above, except that 3H-cholesterol was
omitted from the media during the cholesterol loading step.
2.5. Ex Vivo Macrophage Cholesterol Efflux Experiments. For
efflux assays, plasma was obtained from WT and SAAKO
mice 8 hr aer subcutaneous injection of PBS or LPS
(0.8𝜇𝜇g/g). Mouse serumwas prepared as described [20]. Cel-
lular cholesterol efflux experiments were carried out essen-
tially as described [21, 22]. Brie�y, J774 cells (∼60% con�u-
ent) in 12-well plates were labeled for 48 hr with 0.2𝜇𝜇Ci/mL
[3H]cholesterol (35–50 Ci/mmol, Amersham Biosciences) in
RPMI-1640 supplemented with 10% heat-inactivated FBS,
50 𝜇𝜇g/mL gentamicin, and 50 𝜇𝜇g/mL acLDL. Cells were then
washed three times with PBS containing 1mg/mL BSA (PBS-
BSA) and equilibrated overnight in RPMI-1640 containing
0.2% fatty acid-free BSA (RPMI-BSA). Following two addi-
tional washes with PBS-BSA, cells were harvested to deter-
mine total dpm incorporated (time zero). Efflux to RPMI-
BSAwith or without 2.5% serum from control or LPS-treated
mice was measured over 5 hr at 37∘C. Following the incu-
bation, cell media was collected and centrifuged to remove
detached cells. Radioactivity in the medium was measured
directly in a Packard 𝛽𝛽 liquid scintillation counter. Adherent
cells were washed at 4∘C twice with PBS-BSA and twice
with PBS and then solubilized in 0.1 N NaOH and counted
for radioactivity. Efflux of cellular [3H]-cholesterol was
expressed as the percentage of the total radioactivity incor-
porated into cells at time zero that was present in the media.
2.�. Cholesterol In�ux into �epatoma Cells. Fu5AH hep-
atoma cells, maintained as described above, were seeded
into 12-well plates. When cultures were more than 90%
con�uent, cells were pretreated for 1 hr with 10𝜇𝜇M block
lipid transport-1 (BLT-1) in MEM containing 0.5% FAF-
BSA, to inhibit SR-BI. Control cells were treated with the
DMSO vehicle. Cells were subsequently incubated, in the
presence or absence of BLT-1, in MEM alpha supplemented
with 5% serum obtained from mice at the termination of
RCT experiments (i.e., 24 hr aer administration of [3H]-
cholesterol-labeled macrophages) to monitor the uptake of
[3H]-cholesterolwhich includes both free and esteri�ed [3H]-
cholesterol. Aer 6 hr, cells were washed at 4∘C, 4 times with
PBS containing 0.2% fatty acid-free BSA and twice with PBS,
solubilized in 0.1 N NaOH, and counted for radioactivity.
2.7. Western Blot Analyses. Total liver lysates and liver mem-
brane protein extracts were prepared for western blot anal-
yses essentially as described [23]. Brie�y ∼100mg liver was
homogenized with an Ultra Turrax T8 probe homogenizer
in 1.2 mL 20mM Tris pH 7.5, 2mM MgCl2, and 0.25M
sucrose containing protease inhibitors. Aer centrifugation
at 12000×g for 10min at 4∘C, the supernatant (i.e., total
liver lysate) was used for western blot analyses. Alternatively,
membrane proteins were isolated by centrifuging the total
liver lysate at 100,000×g for 30min at 4∘C; the membrane
protein pellet was resuspended in the homogenization buffer
described above. Protein concentrations of liver lysates and
membrane protein suspensions were determined by BCA
assay (Pierce). Liver proteins were size-fractionated by SDS-
PAGE and immunoblotted with the following antibodies:
anti-human/mouse SR-BI (1 : 1000) [24], anti-mouse/human
ABCG1 (1 : 500; NovusNB400-132), anti-ABCG5 (1 : 10,000;
a generous gi from Dr. Gregory Graf, University of Ken-
tucky). For loading controls liver lysates/membranes were
immunoblotted with anti-𝛽𝛽 actin (1 : 2000; Sigma, A5441)
or anti-mouse calnexin (1 : 2000; Enzo Life Sciences). For
western blot analyses of plasma proteins, aliquots of plasma
(0.3–0.5 𝜇𝜇L) were subjected to SDS-PAGE and immunoblot-
ted using rabbit anti-mouse SAA (De Beer laboratory) or
rabbit anti-mouse SAP (gi from Dr. Mark Pepys, University
College of London, UK). Plasma SAA concentrations were
determined by quantitative immunoblotting using acute
phase mouse HDL with known SAA content as a standard.
2.8. Endotoxin Assay. e Limulus Amebocyte Lysate kit
(Genscript cat. no. L00351) was used to verify that plasma/
serum samples used for ex vivo efflux or in�ux assays
contained less than 0.005 EU/mL of endotoxin.
2.9. Statistical Analyses. Data are expressed as the mean ±
SEM. Results were analyzed by two-way ANOVA with Bon-
ferroni posttest. Signi�cance was de�ned as ∗: 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃; ∗∗:
𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃; ∗∗∗: 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃.
3. Results
�.�. Mice �e�cient in SAA�.� and SAA2.� Mount a �ormal
LPS-Induced Acute Phase Response. According to previous
reports, macrophage-to-feces RCT is reduced in mice during
an LPS-elicited acute phase response [14, 15]. To investigate
whether SAA contributes to this impairment, we carried
out studies using our recently developed gene-targeted mice
that lack both major acute phase SAA isoforms, SAA1.1
and SAA2.1 [13]. In 3 separate studies, the movement of
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3H-cholesterol from macrophages to feces was monitored in
WT and SAAKO mice under both normal and in�ammatory
conditions using an established RCT model [14, 19] (n =
4-5 per group per experiment). An acute phase response
was evoked in mice by injecting a relatively modest dose
of LPS subcutaneously (0.8 𝜇𝜇g/g body weight). As expected,
plasma SAA was readily detected in WT but not SAAKO
mice 28 hr aer LPS injection (Figure 1(a)), reaching values
of ∼130 𝜇𝜇g/mL in the WT mice. e ability of SAAKO mice
to mount an acute phase response was demonstrated by the
marked induction of serum amyloid P component (SAP),
which was present in the plasma at comparable levels in WT
and SAAKO mice 28 hr aer LPS injection (Figure 1(b)).
3.2. SAA Is Not Required for the Reduction in Macrophage to
Plasma RCT during Endotoxemia. For the assessment of in
vivo macrophage RCT, mice were injected intraperitoneally
with 3H-cholesterol-labeled macrophages 4 hr aer adminis-
tration of LPS or PBS control. e initial step of RCT (i.e.,
the movement of 3H-cholesterol from macrophages to the
plasma compartment) was monitored by quantifying plasma
radioactivity 4 hr and 24 hr aer macrophage injection (8 hr
and 28 hr aer LPS injection). In agreement with previous
studies [14, 15], the amount of macrophage-derived 3H-
cholesterol present in plasma was lower in WT mice under-
going an acute phase response compared to control WT
mice, an effect that was statistically signi�cant at the earlier
time point (Figure 2(a)). Similarly, there was signi�cantly
decreased radioactivity in plasma of LPS-injected SAAKO
mice compared to control SAAKO mice when measured at
4 hr (Figure 2(a)). At 24 hr, the amount of radioactive tracer
in plasmawas similar for all four groups ofmice (Figure 2(b)).
To more directly assess whether SAA impacts macrophage
cholesterol efflux, we carried out in vitro cholesterol efflux
assays using cholesterol-loaded J774 cells and serumcollected
from WT and SAAKO mice 8 hr aer LPS or saline injection
(Figure 2(c)). Results from these assays indicated that the
reduced amount of macrophage-derived 3H-cholesterol in
plasma of LPS-injected mice was not associated with a
reduction in the capacity of acute phase serum from either
WT or SAAKO mice to promote cholesterol efflux.
3.3. Hepatic Accumulation ofMacrophage-Derived Cholesterol
Is Not Altered during Endotoxemia, Regardless of the Presence
of SAA. We next investigated whether hepatic accumulation
of macrophage-derived 3H-cholesterol is altered in WT or
SAAKO mice during an acute in�ammatory response. e
amount of radioactivity in livers of LPS-injected WT and
SAAKO mice 24 hr aer macrophage injection was modestly
lower compared to the corresponding control mice, but this
difference did not reach statistical signi�cance in either strain
(Figure 3(a)). According to some [14] but not all [15] reports,
endotoxemia results in transcriptional downregulation of SR-
BI, an important HDL receptor in the liver that mediates
selective lipid uptake fromHDL.Our data indicate that SR-BI
mRNA abundance was signi�cantly reduced in mouse livers
28 hr aer LPS injection, and this downregulation was not
dependent on SAA (Table 1). However, SR-BI protein levels
were not signi�cantly altered in either strain by LPS injection
(Figure 3(b)). Since alterations in HDL-C uptake by the liver
during endotoxemia may not necessarily be evident in static
measures of hepatic 3H-cholesterol content 24 hr following
radiolabeled macrophage injection, we investigated whether
there were any differences in uptake of the radioactive tracer
from the sera of control or LPS-injected WT and SAAKO
mice by Fu5AH hepatoma cells [22, 25]. Uptake studies were
carried out in the presence and absence of 10𝜇𝜇M BLT-1,
whichhas been shown to block SR-BI-mediated selective lipid
uptake from HDL [26]. For all of the serum samples assayed,
BLT-1 reduced the uptake of the radioactive tracer ∼30%
(Figure 3(c)), suggesting that only a portion of hepatic uptake
of the macrophage-derived radioactive tracer was mediated
by SR-BI. Furthermore, our data indicated no signi�cant
differences in the uptake of the radioactive tracer from serum
collected from control or LPS-injected mice, regardless of the
presence of SAA (Figure 3(c)).
3.4. SAA Has Limited Impact on Impaired Macrophage to Bile
and Feces RCT during Endotoxemia. �ndotoxemia signi�-
cantly impaired biliary and fecal excretion of macrophage-
derived 3H-cholesterol in WT mice (Figures 4(a) and 4(b)),
in line with previously published data [14, 15]. At 24 hr aer
macrophage injection, the amount of radioactivity present
in the bile and feces of LPS-injected WT mice was reduced
36% and 80%, respectively, compared to control WT mice.
On the other hand, endotoxemia did not signi�cantly impact
the amount ofmacrophage-derived 3H-cholesterol present in
bile of SAAKO mice, and fecal excretion was reduced by only
45% (Figures 4(a) and 4(b)). us, our results con�rm pre-
vious �ndings that macrophage-to-feces RCT is signi�cantly
reduced in mice undergoing an acute phase response and
establishes that SAA has limited impact on this impairment.
3.�. De�ciency of SAA Does Not Impact the E�ect of In�am-
mation on Hepatic Expression of Enzymes and Transporters
Involved in Cholesterol Flux. Previous studies have estab-
lished that hepatic expression of genes involved in cholesterol
transport and biliary excretion is altered in mice undergoing
an acute phase response [14, 15]. In our studies, a moderate
dose of LPS had no effect on hepatic expression of ABCA1
or Cyp7A1 mRNA (Table 1) in either WT or SAAKO mice
when assessed 28 hr aer LPS injection. On the other hand,
ABCG1, ABCG5, ABCG8, and ABCB11 expression were
all signi�cantly suppressed aer LPS treatment, and this
suppression was not impacted by SAA de�ciency (Table 1).
ere was no evidence that endotoxemia altered hep-
atic ABCG1 or ABCG5 protein in WT or SAAKO mice
(Figures 4(c) and 4(d)).
3.6. Peritoneal Injection of Cholesterol-Loaded J774 Cells
Induces a Transient In�ammatory Response in C�7BL�6
Mice. In the course of our in vivo RCT experiments we
routinely monitored the extent of induction of in�ammation
in LPS-injected mice. Since the SAAKO mice do not
express the major mouse acute phase isoforms SAA1.1 and
SAA2.1, we assessed the expression of serum amyloid P
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F 1: SAAKO mice are capable of mounting an acute phase response. WT and SAAKO mice were injected subcutaneously with 0.8 𝜇𝜇g/g
LPS followed 4 hr later by an intraperitoneal injection of 3H-cholesterol-labeled J774 macrophages. Control WT mice received PBS only.
Aliquots of plasma collected from individual mice 24 hr aer macrophage administration (28 hr aer LPS) were subjected to SDS-PAGE and
immunoblotted using (a) rabbit anti-mouse SAA; and (b) rabbit anti-mouse SAP.
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F 2: SAA does not contribute to reduced macrophage to plasma RCT during an acute phase response. WT and SAAKO mice were
injected subcutaneously with PBS or 0.8 𝜇𝜇g/g LPS as indicated, followed by an intraperitoneal injection of 3H-cholesterol-labeled J774
macrophages 4 hr later. Radioactivity in plasma was determined 4 hr (a) and 24 hr (b) aer macrophage injection (8 hr and 28 hr aer
LPS injection). e data shown in (a) and (b) were compiled from 3 separate experiments (n = 4-5 mice per group per experiment) aer
normalization to the PBS-injected WT mice. For the 3 experiments, radioactivity recovered in plasma of control WT mice at 4 and 24 hr
ranged from 1.0% to 2.4% and 2.0% to 5.0% of the injected radioactivity, respectively. (c) Cholesterol efflux assays were carried out using J774
cells as described in Materials and Methods using serum (2.5% v : v) collected 8 hr aer administration of LPS (0.8 𝜇𝜇g/g body weight; 𝑛𝑛 𝑛 𝑛).
Values are the mean ± SEM; ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑛, ∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃.
component (SAP), another major acute phase reactant in
mice. Unexpectedly, we readily detected SAP in the plasma of
all mice injected with J774 macrophages, irrespective of LPS
administration (data not shown). is �nding prompted us
to investigate the possibility that the experimental protocol
itself produced an in�ammatory response in mice. To this
end, J774 macrophage foam cells were prepared according to
the protocol for RCT and injected into WT mice 4 hr aer
administration of either PBS or LPS (“0 hr” on Figure 5(a)),
and plasma samples were collected at selected intervals
during the course of the experiment and immunoblotted
for SAA. As expected, LPS elicited a robust in�ammatory
response, as evidenced by a marked increase in plasma SAA
thatwas detectable 4 hr aer LPS injection and persisted for at
least 48 hr (Figure 5(a)). Notably, intraperitoneal administra-
tion of J774 macrophages also evoked a robust in�ammatory
response that was detectable 4 hr aer the injection of the
cells, increased by 24 hr, and was still evident at 48 hr aer
administration (Figure 5(a)). is �nding suggested that
intraperitoneal administration of allogeneic macrophages
6 Journal of Lipids
1.25
1
0.75
0.5
0.25n
o
rm
al
iz
ed
 t
o
 c
o
n
tr
o
l W
T
SAAKO
LPS
WT
− + − +
L
iv
er
 r
ad
io
ac
ti
vi
ty
(a)
1.25
1
0.75
0.5
0.25
LPS
SAAKOWT
− + − +
SR-BI
Actin
H
ep
at
ic
 S
R
-B
I
n
o
rm
al
iz
ed
 t
o
β
ac
ti
n
(b)
15
10
5
C
h
o
le
st
er
o
l 
in
fl
u
x
/6
 h
r 
(%
)
−BLT
+BLT
SAAKO
LPS
WT
− + − +
(c)
F 3: Endotoxemia does not alter hepatic accumulation of macrophage-derived 3H-cholesterol, regardless of the presence of SAA. WT
and SAAKOmicewere injected subcutaneously with PBS or 0.8 𝜇𝜇g/g LPS as indicated, followed by intraperitoneal injection of 3H-cholesterol-
labeled J774macrophages 4 hr later. (a) Radioactivity in liver was determined 24 hr aermacrophage injection (28 hr aer LPS injection).e
data shown were compiled from 3 separate experiments (n = 4-5 per group per experiment) aer normalization to PBS-injected WT mice.
Values are themean± SEM. Liver counts for PBS-injectedWT and SAAKOmicewere similar, ranging from 3.9% to 8.5% of the injected tracer
for the 3 experiments. (b) SR-BI in total liver lysates (10 𝜇𝜇g protein) was detected by immunoblotting and �uanti�ed by densitometry. Results
from each of the 3 experiments (n = 4-5 per group per experiment) were expressed relative to PBS-injected WT mice aer normalization
to 𝛽𝛽-actin. A representative western blot is shown. (c) Fu5AH hepatoma cells were preincubated for 1 hr with or without 10 𝜇𝜇M BLT-1 and
then for 6 hr with media ± BLT-1 supplemented with 5% serum obtained from mice 24 hr aer administration of 3H-cholesterol-labeled
macrophages (28 hr aer LPS injection). e amount of radioactivity that was taken up by cells in the presence of BLT-1 is indicated by the
shaded portion of the bars.
may promote an in�ammatory response in mice (J774
cells were originally derived from the BALB/c strain). To
investigate this possibility, we carried out parallel studies in
whichC57BL/6micewere injectedwith either LPS, J774 cells,
or syngeneic bone-marrow-derived macrophages. BMMs
from C57BL/6 mice and J774 macrophages were converted
to foam cells according to the protocol for RCT experiments,
except that 3H-cholesterol was omitted during cholesterol
loading. e cells were then injected into C57BL/6 mice 4 hr
aer administration of either PBS or LPS, and plasma samples
were immunoblotted for SAA 24 hr aer injection of cells
(Figure 5(b)), a time when SAA was markedly induced in the
previous study (Figure 5(a)). Whereas injection of J774 cells
elicited a marked increase in plasma SAA (corresponding to
∼57% of the level evoked by a moderate dose (0.8 𝜇𝜇g/g body
weight) of LPS; Figure 5(c)), SAA was virtually undetectable
in mouse plasma 24 hr aer BMM injection, corresponding
to ∼8% of the amount elicited by LPS.
4. Discussion
Based on a number of large population studies, it is recog-
nized that plasma levels of HDL and its major apolipoprotein
apoA-I are inversely correlated with the risk of atherosclero-
sis. One of the most widely accepted mechanisms to explain
HDL’s cardioprotective effect is its role in RCT, whereby HDL
promotes the removal of excess cholesterol from peripheral
cells, including macrophage foam cells in the vessel wall,
Journal of Lipids 7
T 1: Hepatic gene expression levels in control and LPS-treated mice.
Gene WT SAAKO
PBS LPS PBS LPS
SR-BI 1.00 ± 0.06 0.42 ± 0.05∗∗∗ 0.77 ± 0.06 0.56 ± 0.07∗
Cyp7A1 1.00 ± 0.20 0.28 ± 0.15 1.73 ± 0.35 0.94 ± 0.30
ABCA1 1.00 ± 0.06 1.22 ± 0.12 1.06 ± 0.11 1.01 ± 0.11
ABCG1 1.00 ± 0.05 0.43 ± 0.04∗∗∗ 0.99 ± 0.08 0.47 ± 0.06∗∗∗
ABCG5 1.00 ± 0.07 0.38 ± 0.03∗∗∗ 1.24 ± 0.18 0.41 ± 0.04∗∗∗
ABCG8 1.00 ± 0.10 0.23 ± 0.02∗∗∗ 1.24 ± 0.16 0.28 ± 0.04∗∗∗
ABCB11 1.00 ± 0.05 0.22 ± 0.06∗∗∗ 0.97 ± 0.11 0.42 ± 0.09∗∗∗
Values are expressed relative to control WT mice aer normalization to GAPDH mRNA.
Data represent mean ± SEM, 𝑛𝑛 𝑛 𝑛𝑛.
∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑛, ∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑛, compared to corresponding PBS-treated mice.
and delivery of cholesterol to the liver for excretion. e
RCT pathway involves several steps: (1) mobilization of
cellular cholesterol and efflux to HDL or HDL-derived lipid-
poor apolipoproteins; (2) esteri�cation of free cholesterol in
HDL to form cholesteryl ester (CE) by lecithin-cholesterol
acyltransferase; (3) receptor-mediated uptake of HDL-CE
by hepatocytes, either selectively by SR-BI or via whole
particle uptake through a poorly de�ned pathway; and
(4) deesteri�cation and excretion of cholesterol into bile,
either in the form of free cholesterol or as bile acids. In
species that express cholesterol ester transfer protein (CETP),
including humans but not mice, an alternate pathway for
RCT is through the transfer of HDL-CE to apoB-containing
lipoproteins and their subsequent uptake into the liver. e
extent to which in�ammation impacts the capacity of HDL
to participate in RCT has signi�cant clinical relevance, given
the increasing incidence of chronic in�ammatory conditions
in humans, including rheumatoid arthritis, type 2 diabetes;
and the metabolic syndrome; all of which are associated with
an increased risk for atherosclerotic cardiovascular disease.
Data from this study agrees with earlier reports [14–16] that
acute in�ammation impairs steps in the RCT pathway when
assessed in an establishedmacrophage-to-fecesmousemodel
and determines that acute phase SAA has little impact on this
impairment. We also determined that in the established RCT
model, injection of J744 macrophages results in a transient
in�ammatory response.
In our studies, LPS-induced endotoxemia resulted in
an ∼35% decrease in the movement of 3H-cholesterol from
macrophages to the plasma compartment when assessed
4 hr aer macrophage injection. is result is consistent
with previous reports that endotoxemia acutely impairs
macrophage to plasma RCT and supports the conclusion that
the extent of the impairment is related to the magnitude of
the acute phase response [14]. McGillicuddy reported that
while a relatively low dose of LPS (0.3mg/kg s.c.) did not
reduce 3H-cholesterol counts in plasma at any time point
aer macrophage injection, a high dose of LPS (3mg/kg
s.c.) resulted in a signi�cant ∼35% and ∼20% decline in
macrophage to plasma RCTwhenmeasured at 4 hr and 24 hr,
respectively. In a study by another group, a similar dose of
LPS administered i.p. resulted in a 33% and 27% reduction
in the movement of macrophage-derived cholesterol to the
plasma at 6 and 24 hr, respectively [15]. On the other hand,
the moderate dose of LPS used in our study (0.8mg/kg
s.c.) produced an effect that appeared to be more transient,
since a signi�cant difference in the amount of macrophage-
derived cholesterol in plasma of control and LPS-injected
mice was detected 4 hr, but not 24 hr, aer macrophage
injection. Notably, SAA de�ciency did not alter the acute
effect of endotoxemia to reduce macrophage to plasma RCT,
suggesting that the duration of this impairment is not due
to differences in the magnitude of the induction of SAA at
different doses of LPS.
Previous studies have investigated whether SAA impacts
the ability of HDL to carry out individual steps in the
RCT pathway, including cellular cholesterol efflux. Studies
investigating the impact of in�ammation and SAA per se on
cholesterol efflux have been con�icting, depending on the
nature of the HDL and the cell system used in the assay.
In several reports, SAA, either associated with HDL or in
a lipid-free form, was shown to promote cholesterol efflux
through both ABCA1-dependent and ABCA1-independent
mechanisms [27–33]. With regards to ABCG1-dependent
efflux, our group reported that in�ammatory remodeling of
mouse HDL leads to an increase in its capacity to promote
efflux, but the presence of SAA did not play a role in this
enhancing effect [33]. On the other hand, in two recent
studies, SAA-enriched HDL from human subjects under-
going acute sepsis [15] or HDLs isolated from humans or
mice subjected to experimental endotoxemia [14] showed a
reduced capacity to promote macrophage cholesterol efflux.
Using an overexpression approach, Annema et al. concluded
that SAA does not alter the rate of movement of 3H-
cholesterol from macrophages to mouse plasma in vivo in the
absence of an acute phase response [15]. Results from the
current study suggest that serum from mice collected 8 hr
aer LPS injection is not altered in its capacity to stimulate
efflux from cholesterol-loaded J774 macrophages compared
to control serum, regardless of the presence of SAA. us,
at least in mice, the ability of SAA to modulate macrophage
cholesterol efflux appears to be minimal.
Our data indicate that LPS-induced endotoxemia in
either WT or SAAKO mice does not signi�cantly alter
macrophage to liver RCT, consistent with �ndings from
8 Journal of Lipids
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F 4: SAA has little impact on the impairment in biliary and fecal excretion of macrophage-derived 3H-cholesterol during endotoxemia.
WT and SAAKO mice were injected subcutaneously with PBS or 0.8 𝜇𝜇g/g LPS as indicated, followed 4 hr later by intraperitoneal injection
of 3H-cholesterol-labeled J774 macrophages. (a) Radioactivity in bile was determined 24 hr aer macrophage injection. e data shown are
compiled from 3 separate experiments (n = 4-5 per group per experiment) and normalized to the PBS-injected WT mice. Values are the
mean ± SEM; ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃. For each of the 3 experiments, the amount of radioactivity recovered in the bile of PBS-injected WT and SAAKO
mice was similar, ranging from 0.01𝑃 to 0.04𝑃 of injected tracer per 𝜇𝜇L of bile. (b) Feces were collected during the 24 hr RCT experiments,
and the total amount of radioactivity was determined. Due to methodological issues in one of the experiments, data from only 2 experiments
were compiled (n = 5 per group per experiment) and normalized to the PBS-injected WT mice. Values are the mean ± SEM; ∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃;
∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃. For each of the 2 experiments, the amount of radioactivity recovered in feces of PBS-injected WT and SAAKO mice was similar,
ranging from 1.8𝑃–2.6𝑃 of the injected tracer. (c) ABCG1 in liver lysates (40 𝜇𝜇g protein) was identi�ed by immunoblotting and �uanti�ed
by densitometry. Results from each of the 3 experiments (n = 4-5 per group per experiment) were expressed relative to PBS-injected WT
mice aer normalization to 𝛽𝛽-actin. A representative western blot is shown. (d) ABCG5 in liver membranes (50 𝜇𝜇g protein) was detected by
immunoblotting and �uanti�ed by densitometry. Results from each of the 3 experiments (n = 4-5 per group per experiment) were expressed
relative to PBS-injected WT mice aer normalization to calnexin. A representative western blot is shown, with the immature (reticular) and
mature (post-Golgi) forms of ABCG5 indicated with a carat.e band indicated by an asterisk is observed in G5G8-de�cient mice suggesting
that it represents a nonspeci�c signal [23].
earlier studies [14, 15]. While SR-BI mRNA expression
appeared to be signi�cantly reduced in livers of both WT and
SAAKO mice 28 hr aer LPS injection, SR-BI protein levels
were not altered in either strain. Similarly, McGillicuddy
et al. reported signi�cantly reduced hepatic expression of
SR-BI mRNA without a commensurate change in SR-BI
protein 48 hr aer high dose LPS injection [14]. Since hepatic
accumulation of macrophage-derived 3H-cholesterol at a
single time point is in�uenced in opposite directions by the
rates of �ux into and out of the liver, we carried out in vitro
studies using Fu5AH hepatoma cells to determine whether
hepatic uptake of 3H-cholesterol from acute phase plasma
was signi�cantly di�erent compared to control and the extent
to which SAA might impact such uptake. Uptake by Fu5AH
cells was measured in the presence or absence of BLT-1, a
known inhibitor of SR-BI-mediated selective CE uptake [26].
Our data indicated no signi�cant di�erence in either SR-BI-
dependent or SR-BI-independent uptake of the radioactive
tracer from control or LPS-injected mouse serum, regardless
of the presence of SAA. In a previous study by our group we
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F 5: Intraperitoneal injection of J774 cells induces an acute phase response in C57BL/6mice. (a)WTmice were injected subcutaneously
with PBS or 0.8 𝜇𝜇g/g LPS (−4 hr) followed 4 hr later by an intraperitoneal injection of 3H-cholesterol-labeled J774 macrophages (0 hr); 𝑛𝑛 𝑛 𝑛
per treatment). Aliquots of plasma (0.25 𝜇𝜇L) collected from individual mice at the indicated times were subjected to SDS-PAGE, followed by
immunoblotting for SAA. (b) In two parallel studies, C57BL/6mice were injected subcutaneously with PBS or 0.8 𝜇𝜇g/g LPS, and 4 hr later, the
PBS-injectedmicewere injected i.p. with cholesterol-loaded J774macrophages orC57BL/6 BMM, as indicated (𝑛𝑛 𝑛 𝑛 per treatment). Aliquots
of plasma (0.25 𝜇𝜇L) collected from individual mice 28 hr aer PBS/LPS injection (i.e., 24 hr aer macrophage injection) were subjected to
SDS-PAGE, followed by immunoblotting for SAA. (c) Relative plasma SAA concentrations 28 hr aer PBS/LPS injection (i.e., 24 hr aer
macrophage injection) as determined by densitometry (𝑛𝑛 𝑛 𝑛). Values are the mean ± SEM; ∗∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃; ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
concluded that SAA inhibits SR-BI-mediated selective lipid
uptake from HDL [34]. e discrepant �ndings from the
two studies may be due to differences in cell types used for
uptake studies (Fu5AHcells versus stably transfectedChinese
hamster ovary cells), the use of whole serum versus isolated
HDL particles, the amount of SAA associated with the HDL
fraction, and the fact that the earlier study investigated HDL
enriched with SAA in the absence of in�ammation.
McGillicuddy et al. [14] and Annema et al. [15] both
reported that the most pronounced effect of LPS on RCT was
on cholesterol �ux through the liver to the bile and feces. e
decrease in macrophage-to-feces RCT was associated with
a signi�cant reduction in the mRNA expression of genes
involved in cholesterol transport and bile acid synthesis,
including ABCG5, ABCG8, ABCB11, and CYP7A1, suggest-
ing that one compensatory response to endotoxemia may be
to inhibit the excretion of cholesterol out of the body. In
our studies, the amount of macrophage-derived radiotracer
present in the bile and feces of LPS-injected WT mice was
reduced 36% and 80%, respectively, compared to control
WT mice, con�rming the previous studies. e impact of
LPS on bile and feces RCT was only partially ameliorated in
SAAKO mice. As reported previously [14, 15], we show that
hepatic expression of ABCG5, ABCG8, andABCB11mRNAs
is signi�cantly reduced in WT mice 28 hr aer LPS injection.
However, SAA de�ciency did not reverse this suppressive
effect, nor did the reductions in ABCG5 mRNA coincide
with reduced ABCG5 protein expression. us, our studies
would suggest that other mechanisms in addition to effects
on hepatic expression of genes involved in biliary cholesterol
excretion may also play a role in the impairment of RCT
during acute in�ammation. As pointed out by Malik et al.
[16], perturbations in macrophage-to-feces RCT aer LPS
injection could in part be due to non-speci�c metabolic
effects in the liver or intestine that could have a negative
impact. Whether SAA modulates the potential metabolic
effects of in�ammatory stimuli is the subject of ongoing
studies in our laboratory. A nonbiliary, transintestinal route
for neutral sterol excretion has been described [35–38], but
the role of this pathway in macrophage-to-feces RCT has
not been clearly delineated [39, 40]. e possibility that
in�ammation or SAA modulates trans-intestinal cholesterol
excretion merits further study.
An unanticipated outcome of our studies was the �nding
that C57BL/6 mice administered J774 macrophages undergo
a transient acute phase response, as evidenced by a marked
increase in plasma SAA. e in�ammatory response was less
severe and more short-lived than the response evoked by a
modest dose of LPS. Interestingly, bone-marrow cells from
syngeneic mice handled under identical conditions and with
the same reagents did not produce an in�ammatory response.
Our conclusion that SAA has little impact on the impairment
of RCT during in�ammation is not negated by the �nding
that i.p. injection of J774 cells by itself leads to a modest
acute phase response. Nevertheless, the use of syngeneic
primary macrophages may be preferable over macrophage
10 Journal of Lipids
cell lines for in vivo RCT studies that are not intended to
be carried out in the setting of in�ammation, given the
consistent �nding that in�ammation impairs macrophage-
to-feces RCT in this commonly used surrogate model [14–
16]. In summary, our �ndings clearly show that SAA does
not substantially contribute to the impairment of RCT during
in�ammation.
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